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ABSTRACT 
 
Correlation of Dopaminergic and Serotonergic Dysfunction in a Rat 
Model of Parkinson's Disease 
 
Minkyung Lee 
 
Department of Medicine 
The Graduate School, Yonsei University 
 
(Directed by Professor Young Hoon Ryu) 
 
Depression frequently accompanies Parkinson’s disease (PD) and has a great 
impact on patients’ quality of life and disease progression. Previous research 
suggested that dopamine and serotonin systems are closely linked with depression 
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in PD. However, comprehensive studies about the relationship between these two 
neurotransmitter systems are limited. Therefore, the purpose of this study is to 
evaluate the effect of dopaminergic destruction on the serotonergic system in the 
same subject by using consecutive PET imaging. The interconnection between 
motor symptoms and depression was also examined. 
[18F]FP-CIT was applied to assess dopamine transporters and serotonin 1A (5-
HT1A) receptors were evaluated by [
18F]Mefway in unilateral 6-hydroxydopamine 
(6-OHDA) lesioned and sham operated rats. Behavioral tests were used to evaluate 
the severity of symptoms: rotational number for motor impairment and immobility 
time, acquired from the forced swim test for depression. Region-of-interests (ROIs) 
were drawn in the striatum and cerebellum for the dopamine system and 
hippocampus and cerebellum for the 5-HT system. Non-displaceable binding 
potential in the striatum and hippocampus were compared between 6-OHDA and 
sham groups. 
As a result, unilateral 6-OHDA-lesioned rats exhibited significant bilateral 
reduction of hippocampal BPND for 5-HT1A receptors compared with the sham 
group and there was a positive correlation between striatal BPND for DAT. The 
severity of motor symptoms was also closely related to the depression. Taken 
together, the data demonstrate that destruction of the dopaminergic system causes 
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the reduction of the serotonergic system and that the degrees of change in these 
neurotransmitter systems are also related with behavioral impairment in PD.  
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: 5-HT1A receptor, PET, depression, Parkinson's disease 
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I. INTRODUCTION 
 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that 
is characterized by the loss of dopaminergic neurons in the striatum. Dopamine 
(DA) deficiency affects the cortical-basal ganglia circuit, which is mainly related to 
movement1. Therefore, the evaluation of the integrity of motor dysfunction is a 
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major issue for PD. Patients with PD, however, also suffer from non-motor 
symptoms (NMS) such as neuropsychiatric, autonomic and sensory symptoms, as 
well as sleep disorders. Depression is especially the most common neuropsychiatric 
co-morbidity in PD2,3. The prevalence of depression is reported in 20% to 90% of 
PD patients, which is higher than in healthy or other similarly disabled elderly 
control groups4,5. Depression in PD is important because it leads not only to poor 
prognostic influence but also has a great impact on patients’ quality of life6,7 .  
Previous reports have shown that there is an inverse correlation between 
the severity of depression and dopamine transporter (DAT) availability in PD 
patients8,9. This supports that the nigrostriatal circuit is involved in PD-related 
depression. However, the pathophysiology of depression in PD may not be 
restricted to the dopaminergic system since dopamine replacement only partially 
improves depressive symptoms. The serotonin system is strongly implicated in 
mood changes, most notably depression, and multiple lines of evidence 
demonstrated altered serotonergic neurotransmission in PD10-12. Functional imaging 
studies for serotonin transporters also suggest that a malfunction of the serotonergic 
system is related to the occurrence of depression in PD patients13,14. However, there 
are few comprehensive studies about PD-related depression.  
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1. The current concept of Parkinson’s disease.  
 
The traditional concept that the first neuropathological insult leading to PD 
is the degeneration of dopaminergic neurons in the pars compacta of the substantia 
nigra (resulting in depleted levels of the dopamine) has been challenged.  
Parkinson’s can no longer be considered a complex motor disorder characterized by 
extrapyramidal symptoms, but as a progressive multisystem disease with variegated 
neurological and non-motor deficiencies15.  
 
2. The non-motor symptoms of Parkinson’s disease. 
 
 Non-motor symptoms (NMS) compromise symptoms such as mood 
changes, sleep problems, fatigue, autonomic dysfunction, gastrointestinal and 
sensory problems16,17. They represent a huge challenge to the treating physicians 
and allied health colleagues and continue to be a key determinant of patients’ and 
caretakers’ quality of life at huge societal costs18,19. In terms of the frequency and 
impact on the patients' and caretaker's quality of life and disease progression, the 
most troublesome NMS is depression20. 
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A. The neurochemical basis of depression in Parkinson’s disease. 
 
(A) Dopaminergic dysfunction and depression in PD 
 
 Dysfunction of dopaminergic pathways evidently contributes to a range of 
non-motor symptoms in PD, thus highlighting the role of dopaminergic treatments 
to improve certain aspects of NMS21.   
 In a previous report, there was an inverse correlation between the severity 
of anxiety and depression symptoms and left anterior putamen DAT availability in 
PD patients22. This means that there is an association between specific nigrostriatal 
dopamine system deficits and multiple neuropsychiatric symptoms in PD. This 
relationship may be mediated by impairment in frontal–subcortical circuits, as has 
been posited for PD-associated depression23.  
 To date, there several clinical trials have investigated the efficacy of 
dopaminergic drugs on depression. However, they found that dopamine replacement 
only partially improved depressive symptoms. From these results, we can infer that 
the pathophysiology of depression in PD may not be restricted to the dopaminergic 
system.  
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(B) Serotonergic system and depression in PD 
 
Generally, alteration of the serotonergic system is an important factor in 
the pathophysiology of the depression. Specifically, serotonin receptor subtype 1A 
(5-HT1A) has been the most widely investigated and is known to play a central role 
in maintaining stable 5-HT transmission24. In the presynaptic site, they work as 
reuptake modulators of the synaptic 5-HT, causing a decrease in the release of 5-HT 
into terminal fields. 5-HT1A receptors are also located postsynaptically in the 
cortical and limbic area25-27.  
The serotonergic (5-HT) system is strongly implicated in mood related-
NMS of PD. Post-mortem, pathological, and functional imaging studies have 
demonstrated 5-HT signaling dysfunction in PD. In post-mortem studies of patients 
with PD, 5-HT depletion was observed in both the caudate and frontal cortex10,28.  
A pathological study revealed preferential loss of 5-HT in the caudate compared 
with the putamen but relatively low loss of 5-HT (66%) than dopamine (99%)28-,29.  
In vivo imaging studies have also demonstrated the depletion of 5-HT innervations 
to the striatum as measured by decreased 5-HT transporter binding29, 30. 
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3. Positron emission tomography (PET) 
 
PET is a valuable non-invasive imaging technique for studying both 
structural and functional connectivity. A major advantage of PET is its high 
sensitivity (10-9-10-12 M) that allows for detection of the interactions between 
radioligands and their protein targets. This sensitivity is many orders of magnitude 
greater than the sensitivity with magnetic resonance imaging (MRI) (~10-4 M), or 
computed tomography (CT) (~10-3 M)31,32. In PD, PET can assist in the 
identification of dopamine deficiency and the evaluation of neurotransmitter and 
neuroreceptor function in vivo. PET serves as a biomarker and provides insights 
into both motor and non-motor symptoms of PD patients. 
 
4. Purposes of research 
 
The purpose of the present study is to investigate the relationship between 
the dopaminergic and serotonergic systems in the same subject, to assess an 
association between the severity of symptoms and depression in the animal model 
of PD.  
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II. MATERIALS AND METHODS 
 
1. Animals 
 
Seven male Sprague-Dawley (SD) rats (weighing 406.9 ± 34.5 g, mean ± 
SD) unilaterally lesioned with 6-hydroxy dopamine (6-OHDA; Sigma-Aldrich, St. 
Louis, MO, USA) were used. Lesioning protocol was performed as follows. Rats 
were pretreated with desipramine hydrochloride (12.5 mg/kg; intraperitoneal [i.p.] 
injection, 12.5 mg/ml, 0.1 ml/100g) before deep intraperitoneal ketamine/xylazine 
anesthesia (doses of 40 mg/kg and 5 mg/kg, respectively). Each animal’s head was 
shaved and placed in a stereotaxic device (Stoelting Co., Wood Dale, IL, USA) and 
6-OHDA (20 μg/4 μl/site, total of 40 μg 6-OHDA) was injected into two sites in the 
right striatum according to the rat brain atlas33. The injection sites (relative to the 
bregma and dura) were anterior-posterior (AP) +0.5 mm, medial-lateral (ML) 2.5 
mm, dorsal-ventral (DV) −5.0 mm and AP −0.5 mm, ML 4.2 mm, DV-5.0 mm at a 
rate of 1 μl/min using a 26G Hamilton syringe. The inserted needle was withdrawn 
from each location after 5 min, and the wound was sutured. After 5 weeks, PET 
scanning was undertaken. All rats were housed in a temperature- and humidity-
controlled room with a 12-h light/dark cycle and with free access to food and water. 
The exact same procedure was done for the seven control rats (sham group, 
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weighing 401.2 ± 15.5 g, mean ± SD), except that normal saline was administered 
to the striatum. These experimental protocols were approved by the committee for 
the care and use of laboratory animals of Yonsei University College of Medicine. 
 
A. Mechanism of 6-OHDA for dopaminergic neuron destruction 
 
 The 6-OHDA is a hydroxylated analogue of the endogenous dopamine and 
relies on its specific uptake by the dopamine transporter (DAT) and noradrenaline 
transporter (NAT) from the extracellular membrane34. The toxin dose not cross the 
blood-brain barrier, and it is classically injected into intracerebral areas35. In the 
animal model of PD, desmethylimipramine (desipramine hydrochloride) was 
pretreated before administration of 6-OHDA to prevent uptake by noradrenergic 
terminals and to selectively destroy dopaminergic neurons. Intrastriatal injection of 
6-OHDA induces prompt damage of striatal terminals and progressive cell loss of 
dopaminergic neurons36. The neuronal damage following striatal 6-OHDA infusion 
is mainly associated with massive oxidative stress caused by the toxin. Being 
similar to dopamine, 6-OHDA shows high affinity for the dopamine transporter. 
Once in the neuron, 6-OHDA accumulates in the cytosol and undergoes enzymatic 
degradation by monoamine oxidase-A (MAO-A) producing hydrogen peroxide, 
reactive oxygen species (ROS), and radicals as cytotoxic species36. In addition, 6-
12 
 
OHDA can accumulate in the mitochondria, where it inhibits the activity of the 
electron transport chain by blocking complex I37.   
 
2. Assessment of rotational behavior: Striatum destruction  
 
Two weeks after the 6-OHDA injections, contra- or ipsilateral rotational 
behaviors were induced by i.p. injections of D-amphetamine (5 mg/kg). A 
multichannel rotometer system (ROTORAT, MED Associates, Inc., St. Albans, VT, 
USA) was used for the evaluation of rotational behavior. Each animal was placed in 
a cylindrical test chamber for 60 min, and counter-clockwise rotations were 
analyzed. More than 100 rotations/min was considered to be evidence of successful 
lesioning and rats that met this criterion were used for further PET experiments.  
To assess the severity of motor symptoms, the degree of striatal destruction 
was quantified by the rotation number of each rat. The association between motor 
symptoms and DAT availability was examined in the PD group. 
 
A. Motor impairment associated with unilateral 6-OHDA injection 
 
 The 6-OHDA is commonly injected unilaterally in the striatum. Bilateral 
injection induced high mortality rate in the operated animals38. Rats with a 
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unilateral lesion of the striatum show rotational behavior in response to the 
administration of a dopamine agonist. They rotate ipsilaterally when injected with 
amphetamine, which acts as a presynaptic stimulator, by prompting the release of 
dopamine from striatal terminals, particularly on the intact side39. The rotational test 
has been the gold standard for 6-OHDA lesions, because it is objective, reliable, and 
clearly measures striatal dopamine receptor sensitivity40.  
 
3. Radioligand 
 
[18F]FP-CIT was used for DAT imaging and post-synaptic 5-HT1A 
receptors were evaluated by [18F]Mefway. [18F]FP-CIT was obtained from Asan 
Medical Center, Korea and radiosynthesis of [18F]Mefway was performed according 
to methods reported in previous studies41,42.   
 
A. Radioligand for imaging dopamine transporters 
 
DAT is a plasma membrane protein expressed in dopamine neurons. It is 
involved in the regulation of extracellular levels of dopamine43. [18F]-N-3-
fluoropropyl-2b-carbomethoxy-3β-(4-iodophenyl)nortropane ([18F]FP-CIT) is one 
of the DAT tracers most frequently used. It has an advantage that [18F]Mefway is in 
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its use of 18F. Labeling with 18F allows for distribution to centers without a 
cyclotron, resulting in widespread clinical application. Additionally, the lower 
energy of positron provides higher intrinsic resolution44. DAT imaging has been 
widely applied to several central nervous system disorders. The main application 
has been the quantification of the dopaminergic deficit in PD.  
 
B. Radioligands for imaging 5-HT1A receptors 
 
 Many radioligands have been developed for imaging 5-HT1A receptors and 
most of these tracers belong to the structural families of [N-(2-(1-(4-(2-
methoxyphenyl)-piperazinyl)ethyl))-N-(2-(pyridinyl))cyclohexanecarboxamide] 
(WAY-100635), which is a selective and high-affinity 5-HT1A receptor antagonist 
(KD = 0.2 - 0.4 nM)
45-48. Recently, Saigal et al. developed a very promising 
radioligand for human subjects, [18F]Mefway, which has similar binding affinity 
and selectivity to 5-HT1A receptors as [carbonyl-
11C]WAY-10063548.  
 
4. Acquisition of images 
 
Each animal underwent two consecutive PET scans, using [18F]FP-CIT and 
[18F]Mefway with a 25 h interval (Figure 1). All brain PET images were acquired 
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with a Siemens Inveon small animal PET scanner (Siemens Medical Solutions, 
Malvern, PA, USA). After placing anesthetized rats in the gantry of the PET 
scanner, [18F]FP-CIT was injected to the tail vein with an infusion pump for over 1 
min. Tracer accumulation in the brain was investigated by a dynamic PET scan 
during 120 min. Animals had 24 hours of recovery time. Then, the rats were re-
anesthetized and fluconazole (60 mg/kg, OneFlu injection, JW Pharmaceutical, 
Seoul, Korea) was given to suppress spillover of radioactivity from the skull49 
through the tail veins of the anesthetized rats with an infusion pump (Harvard pump 
11 plus, Harvard Apparatus, USA) for 1 hour. Then, the rats were placed in the 
center of the PET scanner gantry. Emission data collection was started at the time of 
[18F]Mefway injection, and radiotracer accumulation in the brain was examined by 
dynamic PET scans over 120 min. After emission, attenuation corrections were 
performed using data from a 10-min transmission scan with a 57Co point source.  
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Figure 1. Time flow for the consecutive PET studies. After 24 hours of PET scan 
(duration 2 hours) with [18F]FP-CIT, fluconazole was intravenously administrated 
for 1 hour. Then, [18F]Mefway was injected, and PET scans were undertaken over 
120 min.  
 
A. Inhibition of [18F]MEFWAY defluorination in vivo 
 
[18F]Mefway undergoes significant defluorination in vivo through the 
activation of cytochrome P450 2E1 (CYP2E1) isozyme50,51. This defluorination 
causes a spillover effect. The spillover effect means that radioactivity in the skull is 
also included in brain regions nearby, causing difficulties for the exact 
quantification of receptor density.  
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According to Choi et al.’s study, fluconazole showed a powerful 
suppression ability of [18F]Mefway defluorination in vivo. Thus, fluconazole was 
given before [18F]Mefway injection49.  
 
5. Image analysis 
 
Raw list mode data were reconstructed in user-defined time frames (10 sec 
× 6 frames, 30 sec × 8 frames, 300 sec × 5 frames, 1800 sec × 3 frames) with voxel 
dimensions of 0.86 × 0.86 × 0.80 mm3 by a 2-dimensional order-subset expectation 
maximization (OSEM) algorithm. The acquired images were evaluated by region-
of-interests (ROIs) analysis via PMOD 3.1 software (PMOD Technologies Ltd., 
Adliswil, Switzerland). 
 For assessment of the dopamine transporters, volumes of interest (VOIs) 
were drawn in the striatum and cerebellum; then, time-activity curves (TACs) of 
[18F]FP-CIT were acquired. Additional VOIs were drawn in the hippocampus and 
cerebellum followed by extraction of TACs using [18F]Mefway. The cerebellum 
was chosen as a reference region for both radioligands because the region contains 
few dopamine transporters and 5-HT1A receptors
52,53. Regional TACs were 
normalized in units of standardized uptake value (SUV) and calculated as 
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[(radioactivity in VOI in kBq/cc) x (body weight in kg)]/[injected dose in MBq] to 
normalize for the differences in weights and administered doses.  
 
6. Kinetic analysis for binding values 
 
We used the cerebellar cortex without the cerebellar vermis as reference 
tissue to obtain regional binding potentials. By using Ichise’s multilinear reference 
tissue model (MRTM), an individual k2’ value was obtained from the TAC of the 
striatum or hippocampus with fixed time for the linearization (t*) at 40 min for both 
radioligands54. Then with these parameters, regional distribution volume ratios 
(DVR) were calculated by using the non-invasive Logan’s graphical analysis 
method55. Estimated non-displaceable binding potentials (BPND) were calculated as 
the relationship: binding potential = DVR - 1. 
 
7. Assessment of duration of immobility: The severity of depression  
The forced swim test was used as an experimental tool for the evaluation 
of depressive moods. Rats rapidly cease attempts to escape and become immobile 
when forced to swim in a restricted space. The prolonged duration of immobility is 
often considered to be behavioral despair and to reflect a state of lowered mood in 
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the animal that can be extrapolated to a condition similar to human depression. Thus, 
it allows a correlation to be made between immobility and the neurotransmitter 
system56. 
After the [18F]Mefway PET, awakened rats were placed in vertical tank (90 
cm height x 20 cm in diameter) containing water (26oC to a depth of 37 cm) for 15 
min. After 24 hours, the rats were given a second forced swim test for 5 min and the 
motion of the rats were recorded by a video camera. These recordings were 
analyzed for the duration of immobility by commercial software (Smart, Panlab 
Harvard apparatus, Spain). The water was replaced between the tested rats to avoid 
the effects of excrement.  
 
8. Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM). 
Differences in BPND values were analyzed with the Student’s t-test. Pearson’s 
correlation coefficient was used to determine relationships between DAT and 5-
HT1A receptors as well as motor and non-motor symptoms. All statistical analyses 
were performed with Prism 5 (ver. 5.04, GraphPad, La Jolla, CA, USA). 
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III. RESULTS 
 
1. Effect of needle injury and confirmation of lesion 
 
To exclude the effects of needle stick injuries, we compared the BPND for 
DAT in the striatum between the right and left striatum of sham-lesion controls. 
There was no statistical difference in BPND for DAT between the bilateral striatums 
of the sham group (Fig 2A). Successful lesioning was confirmed by comparing of 
the BPND for DAT between the lesion and intact striatum in the 6-OHDA lesioned 
rats. BPND for DAT in the lesioned striatum was significantly lower than that of the 
intact striatum (p < 0.0001, Figure 2B). There was no statistical difference in BPND 
for DAT of the intact striatum between the sham and 6-OHDA lesioned rats. 
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Figure 2. Comparison of [18F]FP-CIT BPND in the sham-operated (A) and 
Parkinson's model (B). There were no significant differences between the right and 
left sites in sham group. There was significant reduction in the lesioned site (***p < 
0.0004) compared with the right side of sham-operated rats. Data represent mean ± 
SEM values for four independent experiments. 
 
2. BPND for DAT and severity of motor symptom in the Parkinson's model 
 
The relationship between BPND for DAT in the striatum and the rotational 
number in 6-OHDA lesioned rats is illustrated in Figure 3. Rotation number showed 
an increasing tendency as BPND values for DAT decreased. A negative correlation 
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was found between the lesion side striatal BPND for DAT in 6-OHDA rats and motor 
impairment parameter (R2= 0.79, p = 0.003).  
 
 
Figure 3. The relationship between the BPND for DAT and the severity of motor 
symptoms. As BPND for DAT decreased in the lesion side striatum, the rotational 
number showed a tendency to increase. Dashed line represents the linear regression 
(R2= 0.79, p = 0.003). 
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3. Comparison of BPND for 5-HT1A in sham and 6-OHDA lesioned group 
 
To determine the effect of the destruction of DAT on the serotonergic system, we 
calculated the BPND of [
18F]Mefway in the hippocampus. BPND in the 6-OHDA lesioned 
group was approximately 22 % lower than the sham operated group with statistical 
significance (p = 0.028). In contrast there was no significant difference of BPND for 5-HT1A 
between intact and lesioned striatums in each group (Figure 4). 
 
 
Figure 4. Comparison of [18F]Mefway BPND in the sham-operated (A) and 
Parkinson's model (B). There were no significant differences between the lesion and 
intact sites in both groups. BPND value for the 6-OHDA lesioned group was lower 
for the sham group with statistical significance (p = 0.028). Data represent mean ± 
SEM values for four independent experiments. 
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 4. BPND for 5-HT1A and severity of depression 
 
The relationship between BPND for 5-HT1A and duration of immobility time 
in the 6-OHDA lesioned group is shown in Figure 5. The duration of immobility 
time showed a tendency to increase when the BPND for 5-HT1A was low. A Pearson's 
correlation test revealed a negative correlation between the BPND for DAT in 6-
OHDA and severity of depression (R2= 0.81, p = 0.006).  
 
 
Figure 5. The relationship between BPND for 5-HT1A and depression severity. As 
BPND for 5-HT1A decreased, the duration of immobility time was prolonged. 
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5. The linkage between dopaminergic and serotonin systems  
 
The association between dopaminergic and serotonin systems is 
demonstrated in Figure 6A. Correlation coefficients revealed a positive correlation 
between the hippocampal BPND for 5-HT1A and the lesion side striatal BPND for DAT 
in 6-OHDA rats (R2= 0.66, p = 0.026).  
Additionally, 6-OHDA lesioned rats with severe motor impairment 
demonstrated longer immobility times. A positive correlation (R2 = 0.74, p = 0.014) 
was found between motor impairment and the severity of depression (Figure 6B).   
 
 
Figure 6. The relationship for BPND values between DAT and 5-HT1A receptor (A): 
A positive correlation was noted between the hippocampal BPND for 5-HT1A and the 
lesion side striatal BPND for DAT in the 6-OHDA model. The relationship between 
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severity of motor and depression symptoms (B): As the rotational number increased, 
the immobility time showed a tendency to be prolonged in the PD model.  
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IV. DISCUSSION 
This was the first non-invasive neuroimaging study of the relationship 
between dopaminergic destruction and the serotonergic system in PD by means of 
PET and behavioral tests. Dopaminergic impairment is positively correlated with 
the alteration of the serotonergic system. The severity of motor symptoms also 
showed a close relationship to non-motor symptoms. These results can be 
extrapolated to a condition similar to behavioral impairment in human PD. Thus, 
results of this study may help further the understanding of the pathophysiology for 
depression in PD.  
The HP was selected as an ROI in this study because it is known as a 
major target of 5-HT aﬀerents within the limbic system. The high density of 5-HT 
receptors in the HP57-59 indicates that it plays an important role in mood 
modulation60. For example, several magnetic resonance imaging studies 
demonstrated reduced HP volumes in individuals with depression61-63. A PET study 
of depressive patients who received selective 5-HT reuptake inhibitors showed 
metabolic activity changes in the corticolimbic circuits, including the HP64. 
In the present study, unilateral 6-OHDA lesioned rats were used to 
evaluate PD-related depression because 6-OHDA selectively destroys the 
presynaptic nerve endings of dopaminergic neurons and causes motor impairment in 
rats65,66. In addition, many researchers have already demonstrated that lesions of 
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dopaminergic neurons induced depression-like behaviors67-69. Hypo-dopaminergic 
and hypo–noradrenergic states were often observed in PD. Previous studies focused 
mainly on the dopaminergic system because the cardinal pathological characteristic 
of PD is degeneration of the dopaminergic neurons. However, the deficiency of 
dopamine dose not seem to be the sole cause of the dysfunction since its 
replacement only partially ameliorates PD symptoms such as tremor, bradykinesia, 
muscle rigidity and impaired posture9,70. In addition, the symptoms of PD appeared 
when about 70% of the dopamine-producing cells were damaged71. In light of these 
findings, the evaluation of the serotonergic system in PD has gained interest since 
pathologic, biochemical, and imaging studies indicate a loss of serotonergic neurons 
in PD72. Multiple lines of evidence suggested a diminished availability of serotonin 
transporters (SERT) in PD. However, the reduction of SERT was observed in non-
depressed patients30. Therefore, we focused the integrity of 5-HT1A receptors 
instead of SERT as a marker of serotonergic system changes.  
It is interesting to note that the unilateral destruction of dopamine neurons 
generated bilateral changes in 5-HT1A receptor uptakes. This result is in accordance 
with previous autoradiographic studies. Li and colleagues demonstrated that 
unilateral 6-OHDA lesions evoke bilateral down-regulation of cortical 5-HT2A 
receptors73. Collectively, these findings indicate that 5-HT hypoinnervation in the 
limbic system can occur after 6-OHDA lesioning. There are several possible 
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explanations for the bilateral attenuation of the serotonergic system after destruction 
of the dopaminergic system. 
The first is the reciprocal interaction between dopamine and serotonin74. 
Dopamine activates the serotonin neuron and serotonin inhibits the dopamine 
neuron. Therefore, the deficiency of the dopamine neuron resulting from the 
administration of neurotoxin might cause an inhibition of the serotonin neuron, 
reducing 5-HT in the synapse.  
Second, the intervention of a glucocorticoid hormone-mainly cortisol-in 
humans and corticosteriod in rodents is associated with depression. Past research 
shows an elevation in circulating cortisol in PD patients and an increase in plasma 
corticosterone level in 6-OHDA lesion rats75,76. Diverse stressors activate a wide-
spectrum of interacting neuroendocrine systems. In mammals, the limbic-
hypothalamic-pituitary-adrenal (LHPA) system is a key neuroendocrine component 
of the stress response77. Neurons in the paraventricular nucleus (PVN) of the 
hypothalamus release a corticotrophin-releasing factor (CRF). The CRF stimulates 
the synthesis and secretion of adrenocorticotropic hormone (ACTH) from the 
anterior pituitary. ACTH then stimulates the glucocorticoid-producing adrenal 
cortex. As a result, LHPA elevates serum glucocorticoid level after stressors. 
Increased glucocorticoids cause neuronal damage to the hippocampus78-81. The 
decreased hippocampal volume suggests a mechanism for putative neuronal loss 
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seen within depressive patients either by apoptosis or inhibition of neurogenesis82-84. 
Other mechanisms are, however, also possible, such as reduction of the volume of 
individual neurons or reduction of glia tissue85. Moreover, glucocorticoid inhibits 
the activity of the tryptophane hydroxylase (TPH)86. 5-HT1A receptors are highly 
concentrated in the hippocampus81 and serotonin is biosynthesized from L-
tryptophan via TPH and amino acid decarboxylase86,87. Suppressed TPH activity 
makes serotonin concentration decrease followed by a down-regulation of the 5-
HT1A in the plasma membrane, Thus, stressors may induce the demolition of 
hippocampal 5-HT1A receptors and reduce 5-HT1A receptor density. 
A third possibility is involvement of habenula nucleus. Located at the 
thalamus, this highly conserved structure can be divided into the medial (MHb) and 
lateral habenula (LHb). The habenula receives inputs from the limbic system and 
basal ganglia88. LHb neurons project bilaterally to the SNc and ventral tegmental 
area (VTA), which are involved in the release of dopamine and 5-HT. It also 
projects to the median raphe nucleus (MRN) and dorsal raphe nucleus (DRN), 
which are also involved in 5-HT release. Efferent projections from the LHb 
terminate in variable structures, including nuclei of monoaminergic neurons; thus, it 
influences monoaminergic system modulation89. The habenula has been shown to 
be hyperactive in patients with major depression90. Based on this concept, Sourani 
et al. hypothesized that increased excitability of the internal globus pallidus in PD 
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leads to enhanced excitability of the LHb, which then causes a down-regulation of 
the 5-HT system because efferent projections from the LHb to DRN are inhibitory91.  
Fourth, the 5-HT hypothesis of depression in PD may explain our findings. 
Mayeux suggested that decreased 5-hydroxyindoleacetic acid (5-HIAA) levels in 
cerebrospinal fluid (CSF) in PD patients were associated with a PD subtype 
characterized by susceptibility to depression92. Campanella et al. showed that 
levodopa treatment causes decreased 5-HIAA CSF levels and depressive symptoms 
in PD patients93,94. In addition, post-mortem studies of PD human brains revealed 
decreased striatal 5-HT and 5-HIAA. The authors of these reports suggested that 5-
HT cell loss in the raphe nuclei occurs prior to dopaminergic cell death10,12,95. 
Moreover, 5-HT1A receptor adaptation will occur in the case of diminished synaptic 
levels of 5-HT. Previous studies using a chronic Parkinsonian monkey and a 6-
OHDA lesioned rat model revealed 5-HT neuron loss in the dorsal raphe nuclei 
(DRN) and decreased 5-HT content in the hippocampus96,97 (Frechilla et al., 2001; 
Wang et al., 2009). These results imply a decrease in total 5-HT innervation. In this 
state, post-synaptic 5-HT1A receptor density is influenced by the reduction in 
innervation98. In the early phase following lesioning, post-synaptic 5-HT1A receptors 
become hypersensitive to compensate for the loss of 5-HT99. In the chronic phase, 
these receptors will be internalized. We found a reduction of BPND in the lesioned 
group, indicating that post-synaptic 5-HT1A receptor density was significantly 
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reduced at 5 weeks after 6-OHDA lesioning. Further research will be needed to 
demonstrate receptor density alterations using an early phase lesion in the PD model. 
Fifth, depressive mood of 6-OHDA rats itself can be a cause of depression. 
Behavioral studies of a 6-OHDA-lesioned rat using the forced swim test, a widely 
used method for assessing depression-like behavior in rodents, demonstrated shorter 
latency and longer duration of floating, suggesting that striatal lesions induce 
depressive mood68,69,100,101. 
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V. CONCLUSION 
 
 The present study demonstrated that the destruction of the dopaminergic 
system causes the reduction of the serotonergic system. There was a positive 
correlation between dopaminergic deficit and serotonergic impairment in terms of 
binding potential. Degrees of change in these neurotransmitter systems were also 
related with the severity of motor and depression symptoms. Our data confirm the 
existence of a link between dopaminergic and serotonergic systems and support the 
crucial role of these neurotransmitters in modulating depression in PD. 
Confirmation of these findings may improve the understanding of the 
pathophysiology of depression in PD and will lead to the development of adequate 
replacement strategies for the treatment of PD patients with depression. 
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ABSTRACT (IN KOREAN)  
 
 
설치류의 파킨슨병 모델에서 도파민계 및 세로토닌계 장애의  
상호 연관성 
 
<지도교수 유영훈> 
 
연세대학교 대학원 의학과 
이민경 
 
 우울증은 파킨슨병에 흔히 동반되며, 환자의 삶의 질과 병의 
진행에 많은 영향을 끼치는 것으로 알려져 있다. 이전 연구 결과들을 
토대로 보면, 도파민계와 세로토닌계는 파킨슨병에 동반된 우울증과 
밀접한 연관이 있는 것으로 여겨진다. 하지만, 아직까지 이 두 시스템 
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사이의 연관성에 중점을 둔, 통합 연구는 많지 않다. 따라서 이번 연구의 
목적은 한 개체 내에서 도파민계의 소실에 따른 세로 토닌계의 변화를 
PET 영상을 통해 분석하고자 하였다. 더불어, 운동 합병증과 우울증의 
상호 연관성 또한 알아보았다.  
 파킨슨 병에 대한 모델로는 편측 선조체에 6-OHDA 를 투여한 
랫트(unilateral 6-OHDA rat)를 사용하였고, 대조군으로는 편측 선조체에 
생리 식염수를 주사한 랫트가 사용되었다. 두 그룹에서 [18F]FP-CIT 는 
도파민 운반체 영상화에 적용하였으며, [18F]Mefway 를 5-HT1A 수용체는 
영상화에 사용하였다. 운동 합병증의 정도는 도파민 효능 약물 투여로 
발현된 회전 운동으로 평가하였고, 우울증의 심각도는 강제 수영 부하 
시험(forced swim test)에서 부동 시간을 측정하여 평가하였다. PET 영상을 
분석함에 있어 도파민계 영상에서는 선조체와 소뇌를, 세로토닌계 
영상에서는 해마와 소뇌를 관심 영역으로 설정하였다. 이후, 6-OHDA 
랫트 그룹과 대조군 사이에 해마 및 선조체의 결합능 차이를 비교하였다. 
 결과적으로, 편측 6-OHDA 랫트에서 해마의 5-HT1A 수용체 
결합능이 대조군 대비 양측에서 현저하게 감소하였고, 선조체의 도파민 
운반체의 결합능과 해마의 5-HT1A 수용체 결합능 사이에는 양의 상관 
관계가 있음을 확인할 수 있었다. 또한, 운동 합병증의 정도와 우울증의 
심각도 역시 밀접한 연관성을 보였다. 
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 이를 종합해 볼 때, 연구의 결과는 도파민계의 소실이 
세로토닌계의 감소를 야기한다는 것과 이 두 신경전달시스템의 변화 
정도가 파킨슨병 환자의 운동 합병증 및 우울증의 심각도와 연관되어 
있음을 시사한다.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 핵심되는 말: 5-HT1A 수용체, PET, 우울증, 파킨슨 병 
